Bactericidal In Vitro Activity of a Tissue-Achievable Concentration of Cefazolin against Methicillin-Resistant .

Methicillin-resistant (MRSA) is a major cause of skin and soft tissue infections and their recurrences. Although traditionally not considered for use against MRSA, cefazolin presents a possible option when administered using ultrasonic drug dispersion (UD2). This novel technique localizes delivery of drug into the subcutaneous tissue and achieves concentrations that exceed the minimum inhibitory concentrations (MICs) of most clinical MRSA isolates.

Cefazolin potency against methicillin-resistant : a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections.

Introduction: Despite aggressive medical and surgical management, the resolution of skin and skin structure infections is often difficult due to insufficient host response, reduced drug penetration, and a high prevalence of resistance organisms such as methicillin-resistant (MRSA). As a result of these factors, conventional management often consists of prolonged broad-spectrum systemic antimicrobials. An alternative therapy in development, ultrasonic drug dispersion (UDD), uses a subcutaneous injection followed by external trans-cutaneous ultrasound to deliver high tissue concentrations of cefazolin with limited systemic exposure.

Protecting exposed tissues with external ultrasonic super-hydration.

The author contends that a technique preventing dehydration of exposed tissues, such as external ultrasonic super-hydration, will result in a lower morbidity rate, decreasing deep tissue pain, susceptibility to infection, fat necrosis, wound dehiscence, and improving recovery times. He discusses how he uses this technique in his aesthetic surgery practice.